Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Blackrock Inc (BLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Blackrock Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Blackrock Inc trades at $986.07 (market cap $156.46B). The key difference: Blackrock Inc is far larger — about 34.8× ACADIA Pharmaceuticals Inc.'s market cap, and Blackrock Inc pays a 2.27% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BLK | |
|---|---|---|
Market Cap | $4.49B | $156.46B |
Sector | Health | Financials |
52-Week High | $28.06 | $1.20K |
52-Week Low | $20.06 | $922.90 |
Enterprise Value | $3.69B | $158.28B |
Volume | — | 641,547 |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BlackRock (BLK) trades at $1,009.43, up 1.38% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $12.53 exceeding expectations. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights expansion into Nasdaq-100 ETFs and Bitcoin ETF offerings, positioning for growth in private markets and AI-driven demand.
Outlook remains positive with a consensus price target of $1,260, reflecting 25% upside. Key risks include volatile cash flows and competitive pressures in ETF markets. Institutional sentiment is strongly bullish, with 76% of analysts rating Buy. Earnings on July 15 will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
